180 related articles for article (PubMed ID: 38254882)
1. MUC1 Drives the Progression and Chemoresistance of Clear Cell Renal Carcinomas.
Bourdon E; Swierczewski T; Goujon M; Boukrout N; Fellah S; Van der Hauwaert C; Larrue R; Lefebvre B; Van Seuningen I; Cauffiez C; Pottier N; Perrais M
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254882
[TBL] [Abstract][Full Text] [Related]
2. MUC1 Expression Affects the Immunoflogosis in Renal Cell Carcinoma Microenvironment through Complement System Activation and Immune Infiltrate Modulation.
Lucarelli G; Netti GS; Rutigliano M; Lasorsa F; Loizzo D; Milella M; Schirinzi A; Fontana A; Di Serio F; Tamma R; Ribatti D; Battaglia M; Ranieri E; Ditonno P
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902242
[TBL] [Abstract][Full Text] [Related]
3. MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome.
Lucarelli G; Rutigliano M; Loizzo D; di Meo NA; Lasorsa F; Mastropasqua M; Maiorano E; Bizzoca C; Vincenti L; Battaglia M; Ditonno P
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430448
[TBL] [Abstract][Full Text] [Related]
4. The Glycosylated
Miyazaki K; Kishimoto H; Kobayashi H; Suzuki A; Higuchi K; Shirasaka Y; Inoue K
Mol Pharmacol; 2023 Mar; 103(3):166-175. PubMed ID: 36804202
[TBL] [Abstract][Full Text] [Related]
5. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression.
Aubert S; Fauquette V; Hémon B; Lepoivre R; Briez N; Bernard D; Van Seuningen I; Leroy X; Perrais M
Cancer Res; 2009 Jul; 69(14):5707-15. PubMed ID: 19549898
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of MUC1 and sialyl Lewis antigens in different areas of clear renal cell carcinoma.
Borzym-Kluczyk M; Radziejewska I; Cechowska-Pasko M
Clin Exp Nephrol; 2015 Aug; 19(4):732-7. PubMed ID: 25091456
[TBL] [Abstract][Full Text] [Related]
8. MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner.
Jin W; Liao X; Lv Y; Pang Z; Wang Y; Li Q; Liao Y; Ye Q; Chen G; Zhao K; Huang L
Cell Death Dis; 2017 Aug; 8(8):e2980. PubMed ID: 28796259
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein.
Nassar H; Pansare V; Zhang H; Che M; Sakr W; Ali-Fehmi R; Grignon D; Sarkar F; Cheng J; Adsay V
Mod Pathol; 2004 Sep; 17(9):1045-50. PubMed ID: 15154007
[TBL] [Abstract][Full Text] [Related]
10. MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.
Alam M; Bouillez A; Tagde A; Ahmad R; Rajabi H; Maeda T; Hiraki M; Suzuki Y; Kufe D
Mol Cancer Res; 2016 Dec; 14(12):1266-1276. PubMed ID: 27658423
[TBL] [Abstract][Full Text] [Related]
11. MUC1: a multifaceted oncoprotein with a key role in cancer progression.
Nath S; Mukherjee P
Trends Mol Med; 2014 Jun; 20(6):332-42. PubMed ID: 24667139
[TBL] [Abstract][Full Text] [Related]
12. Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine.
Lobo NC; Gedye C; Apostoli AJ; Brown KR; Paterson J; Stickle N; Robinette M; Fleshner N; Hamilton RJ; Kulkarni G; Zlotta A; Evans A; Finelli A; Moffat J; Jewett MA; Ailles L
BMC Cancer; 2016 Jul; 16():485. PubMed ID: 27422173
[TBL] [Abstract][Full Text] [Related]
13. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.
Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B
Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575
[TBL] [Abstract][Full Text] [Related]
14. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma.
Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M
Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159
[TBL] [Abstract][Full Text] [Related]
15. Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases.
Langner C; Ratschek M; Rehak P; Schips L; Zigeuner R
Mod Pathol; 2004 Feb; 17(2):180-8. PubMed ID: 14657952
[TBL] [Abstract][Full Text] [Related]
16. LncRNA LINC00667 gets involved in clear cell renal cell carcinoma development and chemoresistance by regulating the miR-143-3p/ZEB1 axis.
Zhao J; Chen P; Tan C; Cheng X; Zhang W; Shen C; Zhang D
Aging (Albany NY); 2023 Oct; 15(19):10057-10071. PubMed ID: 37827696
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis.
Kaur S; Momi N; Chakraborty S; Wagner DG; Horn AJ; Lele SM; Theodorescu D; Batra SK
PLoS One; 2014; 9(3):e92742. PubMed ID: 24671186
[TBL] [Abstract][Full Text] [Related]
18. Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer.
Zhang L; Ma T; Brozick J; Babalola K; Budiu R; Tseng G; Vlad AM
Oncogene; 2016 Sep; 35(38):5010-20. PubMed ID: 26973247
[TBL] [Abstract][Full Text] [Related]
19. Human MUC1 mucin: a potent glandular morphogen.
Hudson MJ; Stamp GW; Chaudhary KS; Hewitt R; Stubbs AP; Abel PD; Lalani EN
J Pathol; 2001 Jul; 194(3):373-83. PubMed ID: 11439371
[TBL] [Abstract][Full Text] [Related]
20. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
